

Pathophysiology of Primary Headaches

The Headache Centre

Guy's & St Thomas's NHS Foundation Trust &
Wolfson SPaRC, King's College London

Disclosures


Potential COI	Organisation
Advisory/ Scientific Boards	Eli Lilly, Neuresta, Zenith Scientific
Speaker / Speakers Boards	Eli Lilly, AbbVie, Pfizer, TEVA
Grant support for research or education	AbbVie, Pfizer, Medical Research Foundation, Brain Research UK, Migraine Trust, Medical Research Council, National Institute of Health, Ipsen
Editorial Board	Cephalgia, Journal of Headache and Pain, Journal of Clinical Medicine, Frontiers in Neurology, Toxins
Author royalties	None
Other	Trustee of the International Headache Society, Chair of Headache SIG of British Pain Society, Lead of National Audit for Headache Disorders/National Audit for Migraine- UK

International Classification of Headache Disorders


International Headache Society, 3rd Edition , 2018

	IHS code	Classification
Primary headaches	1.	Migraine
	2.	Tension-type headache
	3.	Trigeminal autonomic cephalalgias
	4.	Other primary headache disorders
Secondary headaches	5.	Headache attributed to trauma or injury to the head and/or neck
	6.	Headache attributed to cranial or cervical vascular disorder
	7.	Headache attributed to non-vascular intracranial disorder
	8.	Headache attributed to a substance or its withdrawal
	9.	Headache attributed to infection
	10.	Headache attributed to disorder of homoeostasis
	11.	Headache or facial pain attributed to disorder of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth or other facial or cervical structures
Painful cranial neuropathies, other facial pains and other headaches	12.	Headache attributed to psychiatric disorder
	13.	Painful lesions of the cranial nerves and other facial pain
	14.	Other headache disorders

Ascending Trigeminothalamic Pathway – Sensory Information from the Region of Head and Neck



Nerve fibres innervating the cranial circulation – Neuropeptides and Trigeminovascular activation



AChE, acetylcholinesterase; ATP, Adenosine triphosphate; CGRP, Calcitonin gene-related peptide; NPY, Neuropeptide Y; NA, noradrenaline ; NKA, neurokinin A; NOS, Nitric oxide synthase; PACAP, Pituitary Adenylate Cyclase-Activating Polypeptide; PHM, Peptide histidine methionine SP, substance P; VIP, Vasoactive intestinal peptide

International Classification of Headache Disorders


International Headache Society, 3rd Edition , 2018

	IHS code	Classification
Primary headaches	1.	Migraine
	2.	Tension-type headache
	3.	Trigeminal autonomic cephalalgias
	4.	Other primary headache disorders
Secondary headaches	5.	Headache attributed to trauma or injury to the head and/or neck
	6.	Headache attributed to cranial or cervical vascular disorder
	7.	Headache attributed to non-vascular intracranial disorder
	8.	Headache attributed to a substance or its withdrawal
	9.	Headache attributed to infection
	10.	Headache attributed to disorder of homoeostasis
	11.	Headache or facial pain attributed to disorder of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth or other facial or cervical structures
Painful cranial neuropathies, other facial pains and other headaches	12.	Headache attributed to psychiatric disorder
	13.	Painful lesions of the cranial nerves and other facial pain
	14.	Other headache disorders

Migraine – A Cycling Disorder

A clinical syndrome characterized by episodic attacks of head pain and associated symptoms, such as nausea, sensitivity to light, sound, or intolerance to head movement

Episodic migraine



Migraine Attack - More than a headache

Characterised by different phases, including a headache phase, with specific features and associated symptoms¹





Figure adapted from Andreou AP and Edvinsson L. 2019.²

Migraine: Pathophysiology






Migraine: Pathophysiology



**MULTIFACTORIAL
PREDISPOSITION**

**INTERICTAL
PHASE**




Premonitory Phase – Hypothalamic and Cortical Activation


Spontaneous Attacks (PET imaging)







Spontaneous Attacks (fMRI imaging)




GTN-induced Attacks (PET imaging)



Migraine Aura— Cortical Spreading Depression




Migraine Aura— Cortical Spreading Depression



- Slow, self-propagating wave of depolarization of neurons and glia activation
- Results in an initial hyperaemic phase followed by an oligaemic phase
- Does not cross cerebral hemispheres or spreads to deeper brain structures

Migraine Aura— Cortical Spreading Depression



Laser Doppler: Cerebral blood flow measurements



Migraine Aura— Cortical Spreading Depression





Cortical “Waves” in Migraine *Without* Aura – Cortical Hypoperfusion



? Cortical activation of a lower threshold than the one required to develop cortical spreading depression (*silent aura*)?

Ascending Trigeminothalamic Pathway Sensory – Information from the Region of Head and Neck







The Role of the Trigeminal System

- The referred pain patterns of migraine headache are similar to the locations of referred pain after stimulation of cerebral arteries

Wolff's Headache – Stimulation of Meningeal Structures Produces Headache-like Pain




Sensitive structures of the meninges and
areas of referred pain



Correlation of pain and tenderness during
attacks of migraine (★ pain, ● tenderness)

The Role of the Trigeminal System

- The referred pain patterns of migraine headache are similar to the locations of referred pain after stimulation of cerebral arteries
- CGRP levels are increased during a migraine attack




The Role of the Trigeminal System

- The referred pain patterns of migraine headache are similar to the locations of referred pain after stimulation of cerebral arteries
- CGRP levels are increased during a migraine attack
- Chemicals that do not cross the blood-brain barrier can trigger a migraine attack in sufferers (e.g. CGRP, Histamine)



Example: Systemic Administration of CGRP Can Induce Migraine Attacks



The Role of the Trigeminal System

- The referred pain patterns of migraine headache are similar to the locations of referred pain after stimulation of cerebral arteries
- CGRP levels are increased during a migraine attack
- Chemicals that do not cross the blood-brain barrier can trigger a migraine attack in sufferers (CGRP, Histamine)
- Effective migraine treatments do not cross the blood-brain barrier (e.g. Triptans, Botulinum toxin A, CGRP mAbs)

Example: BOTOX® in the Treatment of Chronic Migraine

**Long-term significant reduction of headache days by
BOTOX® – a peripherally acting treatment^{1–3}**

Real world evidence – UK post-NICE appraisal






Figure adapted from Andreou AP, *et al.* 2018.

Glutamate—The Excitatory Neurotransmitter in the Ascending Trigeminal Pathway




How is Migraine Headache Generated Following Hypothalamic Activation?




Brainstem Activation During the Headache Phase

Spontaneous Migraine Attacks




GTN-Triggered Migraine Attacks




Afridi et al., *Brain* 2005;128:932-9; Afridi S. et al., *Arch Neurol* 2005;62:1270-75
Bahra et al., *Lancet* 2001;357:1016-17; Schulte & May. *Brain*, 2016: 139; 1987–1993

Chronic Migraine

- Headache occurring on ≥ 15 or more days/month for more than three months
- At least 8 days per month, have the features of migraine headache (photophobia, phonophobia, worsen by movement, nausea, aura...)





Migraine – A Cycling Disorder with Evolutive Characteristics



Episodic migraine

Chronic migraine




Poor Acute Treatment Associated with Chronic Migraine Risk

American Migraine Prevalence and Prevention Study

- N=5,681 with EM in 2006 → 3.1% progressed to CM

Conclusion:


- Inadequate acute treatment efficacy was associated with an increased risk of new onset CM over the course of 1 year
- Optimal acute treatment might prevent migraine progression




CM, chronic migraine; EM, episodic migraine

Peripheral Sensory Inputs are Important in Sustaining Central Drive in Pain

Peripheral sensitisation



Central sensitisation



Pericranial tissue

Peripheral first-order neuron


Central second-order neuron

Figure adapted from Levy D, *et al.* 2004.


Tension-Type Headache

Tension-type headache vs. Migraine differential diagnosis

TENSION-TYPE HEADACHE



Sensation of pressure or tightness, sometimes spreading into or from the neck



Moderate but steady ache not affected by physical activity




Bilateral pain often described like a band around the head


MIGRAINE



**Sensitivity to light, sound and smell
Sometimes aura before onset**



Moderate to severe pain aggravated by physical activity



Pounding or throbbing pain, often on one side of the head

Pathophysiology of TTH

Unknown

- Presence of pericranial and cervical muscle tenderness in TTH patients during attacks compared to controls
- Mechanical trigger points- Is excess pericranial muscle activity involved in the pathophysiology of TTH?

Ashina M. Cephalalgia 2004;24(3):161-172

Bendtsen L, Ferná' ndez-de-la-Penas C. Curr Pain Headache Rep 2011; 15(6):451-458


Ashina M, Stallknecht B, Bendtsen L, et al. Brain 2002;125(pt 2):320-326

Ashina M, Stallknecht B, Bendtsen L, et al. Cephalalgia 2003;23(2):109-116

Treatment of Tension-type Headache With Botulinum Toxin Type A: A Double-Blind, Placebo-Controlled Study

Jens D. Rollnik, MD; Oliver Tanneberger; Margot Schubert, MD; Udo Schneider, MD;
Reinhard Dengler, MD

(*Headache* 2000;40:300-305)



Results.—After 4, 8, and 12 weeks, no significant differences between placebo and treatment could be observed (with respect to visual analog scale, frequency and duration of headache attacks, consumption of analgesics, pressure pain threshold, total tenderness score, and quality-of-life parameters).

Conclusions.—The findings of our study strongly support the hypothesis that peripheral mechanisms, such as increased muscle tenderness, only play a minor role in the pathogenesis of tension-type headache.

* Botulinum toxin A induces muscle paralysis by cleaving SNAP-25 at the neuromuscular junction

Pathophysiology of TTH

Unknown

- Pericranial and cervical muscle tenderness compared to controls
- Absence of pericranial muscle activity or inflammation




Figure adapted from Levy D, *et al.* 2004.

International Classification of Headache Disorders

International Headache Society, 3rd Edition , 2018

	IHS code	Classification
Primary headaches	1.	Migraine
	2.	Tension-type headache
	3.	Trigeminal autonomic cephalalgias
	4.	Other primary headache disorders
Secondary headaches	5.	Headache attributed to trauma or injury to the head and/or neck
	6.	Headache attributed to cranial or cervical vascular disorder
	7.	Headache attributed to non-vascular intracranial disorder
	8.	Headache attributed to a substance or its withdrawal
	9.	Headache attributed to infection
	10.	Headache attributed to disorder of homoeostasis
	11.	Headache or facial pain attributed to disorder of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth or other facial or cervical structures
	12.	Headache attributed to psychiatric disorder
Painful cranial neuropathies, other facial pains and other headaches	13.	Painful lesions of the cranial nerves and other facial pain
	14.	Other headache disorders

Trigeminal Autonomic Cephalalgias

Trigeminal Autonomic Cephalalgias

3.1 Cluster headache

- 3.1.1 Episodic cluster headache
- 3.1.2 Chronic cluster headache

3.2 Paroxysmal hemicrania

- 3.2.1 Episodic paroxysmal hemicrania
- 3.2.2 Chronic paroxysmal hemicrania

3.3 Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA)

- 3.3.1 Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)
 - 3.3.1.1 Episodic SUNCT
 - 3.3.1.2 Chronic SUNCT
- 3.3.2 Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)
 - 3.3.2.1 Episodic SUNA
 - 3.3.2.2 Chronic SUNA


3.4 Hemicrania continua

- 3.4.1 Hemicrania continua, remitting subtype
- 3.4.2 Hemicrania continua, unremitting subtype


3.5 Probable trigeminal autonomic cephalalgia

Trigeminal Autonomic Cephalalgias (TACs)

- Duration (min)



- Frequency (attacks/day)




* Indomethacin responsive headaches


Trigeminal Autonomic Cephalalgias – Cluster Headache

Cluster Headache (CH) Chronobiology

Circadian rhythmicity



Cirannual rhythmicity



Red line – cluster occurrence/severity improves during the summer months, possibly due to number of daylight hours. Blue line – Clusters occur during the spring and autumn months. Green line – clusters occur around the time of the solstices, possibly due to an inability to synchronize the internal circannual pacemaker.

Cluster Headache (CH) Pathophysiology

Fig. 1 Multi-subject GML analysis shows cerebral activation area in the posterior grey hypothalamus, ipsilateral to the pain side ($P < 0.001$ uncorrected for descriptive purposes), superimposed on a T1-weighted anatomical reference MR image in axial (a) and coronal (b) planes






Fig. 2 Temporal course of the BOLD signals in the hypothalamus ipsilaterally to the pain-side in patient 2. Asymptomatic state (a). Onset of the headache attack and state of pain (b). Administration of sumatriptan (c). Pain relief-state (d). On the horizontal line the number of the 400 GE-EPI acquisitions, is indicated



Spontaneous attacks: Moelli et al., J Headache Pain (2009) 10:11–14


GTN-induced attacks: May et al., The Lancet (1998), 352 (9124), P275-278

Cluster Headache (CH) Pathophysiology






- Posterior hypothalamic activation may modulate signalling through the trigeminocervical complex (TCC)
- Trigeminal fibers activate the parasympathetic system through the superior salivatory nucleus, which in turn activates fibers of the greater petrosal nerve through the sphenopalatine ganglion, activating the trigeminal autonomic reflex and triggering the attack.

Hypothalamic deep brain stimulation in Cluster Headache



- DBS of the posterior hypothalamic region has been proposed as a prophylactic treatment for refractory chronic CH.
- Its efficacy has been reported in several open studies and case series but not confirmed in randomised controlled studies.
- DBS is efficient in about 60–70% of the patients (decrease of attack frequency >50%).
- Risks: rare but serious; intracranial hemorrhage - reserve DBS for medically refractory chronic CH patients.

Neuropeptide Changes During Cluster Headache Attacks



Adapted from Goadsby and Edvinsson L. *Brain*. 1994;117 (Pt 3):427-34



Genetics of Cluster Headache



Research Article | [Open Access](#) | CC BY-NC-ND

Genome-Wide Association Study Identifies Risk Loci for Cluster Headache

Emer O'Connor MB, BCH, BAO, Carmen Fourier MSc, Caroline Ran PhD, Prasanth Sivakumar PhD, Franziska Liesecke PhD, Laura Southgate PhD, Aster V. E. Harder MD ... [See all authors](#) ▾

Chen et al. *The Journal of Headache and Pain* (2022) 23:147
<https://doi.org/10.1186/s10194-022-01517-6>

The Journal of Headache
and Pain

RESEARCH

Open Access


Genome-wide analyses identify novel risk loci for cluster headache in Han Chinese residing in Taiwan




- Identified and replicated several genome-wide significant associations supporting a genetic predisposition in cluster headache
- Downstream analyses implicated immunological processes in the pathogenesis of cluster headache.
- Poly- genic risk score differentiated patients from controls.
- Downstream analyses implicated circadian regulation and immunological processes in the pathogenesis of cluster headache.

Inflammatory Biomarkers in Cluster Headache & Hypothalamic Microinflammation

NF- κ B pathway activation in the posterior hypothalamic area



Andreou lab



Thank you!

Headache Research Lab

Joseph Lloyd
Ana D Pereira
Charlotte Leese
Diego Valiente Cerro
Kenneth Da Silva
Rand Al-Rawi
Ramla Abuukar Abdullahi



MigraineResearch@kcl.ac.uk



@ap_andreou

@GSTT_Headache

<https://www.headache-research.com/>

